Bitcoin groundbreakers share personal stories of how Bitcoin is changing lives for the better. Host Mauricio Di Bartolomeo, co-founder and CSO of Ledn, speaks with leading Bitcoin voices, entrepreneurs, and human rights advocates to hear their unique journey and practical real-world examples of how Bitcoin has made a positive impact in their lives. Brought to you by Ledn, a leading financial services company built for Bitcoin & digital assets. Ledn offers a suite of lending, saving and tradi ...
…
continue reading
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Orthocell reports 98.6% success rate in Striate+™ dental membrane study
MP3•Episode home
Manage episode 418325653 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Orthocell Ltd (ASX:OCC, OTC:ORHHF) CEO and managing director Paul Anderson joins Jonathan Jackson in the Proactive studio to talk through a 98.6% success rate in a post-market clinical study examining the effectiveness of its Striate+™ dental membrane in guided bone regeneration for dental implants. The Striate+™, a resorbable collagen membrane, has been validated through this study as a leading solution in bone and tissue regeneration, supporting Orthocell’s claim of its product being the best choice for such medical procedures. Anderson highlights the membrane's ability to enable high-quality bone and tissue repair, crucial for functional and aesthetically pleasing outcomes in patients. These results, indicating a notable level of bone formation and stability, were obtained from 99 patients, reinforcing the product's efficacy in real-world applications. Orthocell anticipates that the success of the Striate+™ will enhance its visibility among dental professionals and support BioHorizons, its exclusive global distributor, in increasing the product's market adoption. This development is particularly significant given the estimated annual market potential of more than US$700 million for the Striate+ product. The findings are scheduled for presentation at the European Association for Osseintegration (EAO) annual meeting in October 2024. The study also contributes to the clinical data needed for re-certification of EU market approval under the new European Medical Device Regulations (MDR), following an earlier Post-Market Clinical Follow-up (PMCF) study. #ProactiveInvestors #Orthocell #ASX #OTC #DentalImplants, #BoneRegeneration, #StriatePlus, #DentalSurgery, #MedicalDevices, #ClinicalStudy, #TissueRepair, #BioHorizons, #EAO2024, #DentalHealth, #GuidedBoneRegeneration, #CollagenMembrane, #DentalCare, #Osseointegration, #EURegulations, #MedicalResearch, #HealthcareInnovation, #PatientCare, #MedicalTechnology #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
618 episodes
MP3•Episode home
Manage episode 418325653 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Orthocell Ltd (ASX:OCC, OTC:ORHHF) CEO and managing director Paul Anderson joins Jonathan Jackson in the Proactive studio to talk through a 98.6% success rate in a post-market clinical study examining the effectiveness of its Striate+™ dental membrane in guided bone regeneration for dental implants. The Striate+™, a resorbable collagen membrane, has been validated through this study as a leading solution in bone and tissue regeneration, supporting Orthocell’s claim of its product being the best choice for such medical procedures. Anderson highlights the membrane's ability to enable high-quality bone and tissue repair, crucial for functional and aesthetically pleasing outcomes in patients. These results, indicating a notable level of bone formation and stability, were obtained from 99 patients, reinforcing the product's efficacy in real-world applications. Orthocell anticipates that the success of the Striate+™ will enhance its visibility among dental professionals and support BioHorizons, its exclusive global distributor, in increasing the product's market adoption. This development is particularly significant given the estimated annual market potential of more than US$700 million for the Striate+ product. The findings are scheduled for presentation at the European Association for Osseintegration (EAO) annual meeting in October 2024. The study also contributes to the clinical data needed for re-certification of EU market approval under the new European Medical Device Regulations (MDR), following an earlier Post-Market Clinical Follow-up (PMCF) study. #ProactiveInvestors #Orthocell #ASX #OTC #DentalImplants, #BoneRegeneration, #StriatePlus, #DentalSurgery, #MedicalDevices, #ClinicalStudy, #TissueRepair, #BioHorizons, #EAO2024, #DentalHealth, #GuidedBoneRegeneration, #CollagenMembrane, #DentalCare, #Osseointegration, #EURegulations, #MedicalResearch, #HealthcareInnovation, #PatientCare, #MedicalTechnology #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
618 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.